483
Azurity Pharmaceuticals, Inc.Azurity Pharmaceuticals, Inc. – FDA 483, Feb 19, 2025
Record Details
Azurity Pharmaceuticals, Inc. in Wilmington, MA, was inspected and cited for deficiencies in its complaint handling procedures. The firm failed to ensure adequate investigations for drug product appearance issues, including a lack of retain sample examination by its contract manufacturer, which was approved by Azurity's Quality Assurance. This indicates a significant breakdown in quality control and complaint management.
View Company Profile
ID · fbd8eaca-fe0a-415e-8722-8c80ddd8f442
Other documents for Azurity Pharmaceuticals, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.